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Objective: In 1981 McKinlay described “Seven Stages in the Career of a Medical Innovation”.
We wished to examine whether the model ﬁts a modern device life cycle, and to comment on
device manufacturers' inﬂuence on the life cycle. We chose to study the complete life cycle of
TVT Secur, a mesh kit for surgical treatment of stress urinary incontinence in women, from its
marketing in 2006 to device discontinuation for commercial reasons in March 2013.
Methods: A PubMed review was undertaken to identify all published literature related to TVT
Secur from 2006 to November 2014. Each publication was classiﬁed according to McKinlay's
seven stages.
Results: Eighty-three relevant publications from 22 countries were identiﬁed: 4 promising
reports, 1 professional adoption, 0 third-party endorsement, 34 standard procedure, 19
randomised controlled trials (RCTs) from 2010 and mainly describing comparisons with other
TVT family members), 0 professional denunciation of RCT ﬁndings, and 4 erosion and
discreditation.
Conclusions: McKinlay's seven stages model was useful to describe TVT Secur's truncated life
cycle. TVT Secur, fully approved and licensed according to all jurisdictional requirements,
generated many descriptive cohort studies but more rigorous RCT evidence appeared only
half way through its life cycle. Device discontinuation meant that the stage of erosion
and discreditation described by McKinlay occurred after TVT Secur was no longer available..02.008
raduate Medicine. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
licenses/by-nc-nd/4.0/).
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169Surgical device life cycle analysisWe suggest that careful premarket evaluation of safety and effectiveness might decrease the
need for commercial discontinuation of devices, and that post-marketing evaluation is a crucial
mechanism to protect patients from harm.
& 2015 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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On March 31, 2013, Gynecare TVT Secur™ (Gynecare,
Ethicon Inc., Somerville, MA, USA) was removed from the
device market and became no longer available for purchase.
TVT Secur, a member of the Ethicon Gynecare TVT family of
devices, was a surgical device used to treat stress urinary
incontinence in women by placing a polypropylene mesh
tape beneath the urethra, via a single vaginal incision.
Surgery is used as last resort for women who have not
responded to conservative treatments for their stress
incontinence, and who ﬁnd incontinence impacts their
activities and reduces their quality of life.
TVT Secur was licensed for marketing in Europe, USA,
Canada and Australia in 2005/2006 on the premise that the
device was substantially similar to other licensed midure-
thral sling devices [1] such as Ethicon's existing tension-free
retropubic tape, TVT™ and obturator tape, TVT-O™.
Device regulations in these jurisdictions did not require
new evidence of safety and effectiveness [1] to license TVT
Secur, and no studies had been carried out in live humans
before the device was approved [2–4].
In June 2012, Ethicon wrote to physicians announcing that
TVT Secur would be removed from the market the following
year. The announcement emphasized that the company
continued to have conﬁdence in the safety and efﬁcacy of
TVT Secur, and that the decision to discontinue the device
was based on commercial considerations, speciﬁcally related
to the changing regulatory environment and competitive
worldwide market. The regulatory environment is coming
under increasing scrutiny as product advisories related to
transvaginally-implanted surgical mesh appear [5–7], thenumber of withdrawals increases [8] and commentators
criticize the licensing of devices without evidence of safety
or effectiveness [2–4,9]. The pelvic ﬂoor device market is
ﬁercely competitive, including many device manufacturers
each with a variety of competing devices. It is a market
where frequent device changes are needed to ensure
competitiveness [1,10]. In the case of Ethicon, the disconti-
nuation of TVT Secur might have been intended to protect
the sales of the remaining members of the TVT family of
devices (original TVT, TVT-O, TVT Abbrevo™ and TVT
Exact™).
In 1981 sociologist John McKinlay developed a model that
described “Seven Stages in the Career of a Medical Innova-
tion” [11]. The seven stages were described as follows:
Stage 1 – Promising reports: enthusiastic reports about a
new innovation may appear either in the media or as
case reports or uncontrolled observational reports in
medical journals.
Stage 2 – Professional and organizational adoption: the
new innovation is adopted by powerful groups such as
professional associations and larger hospitals.
Stage 3 – Public acceptance and third-party endorse-
ment: the public accepts the innovation as a “good
thing” and the health care system or insurers (as appro-
priate) agree to provide or fund the innovation.
Stage 4 – Standard procedure and observational reports: the
innovation becomes part of usual clinical care while studies
to ascertain its effectiveness begin, usually taking the form
of retrospective studies, case-reports or follow-up studies of
“an arbitrarily selected series of patients who have already
been subjected to the innovation” [11].
S. Ross et al.170Stage 5 – Randomised controlled trials (RCTs): these
more rigorous studies tend to appear after the wide-
spread adoption of an innovation, and often show that it
is less effective than indicated by earlier observational
studies.
Stage 6 – Professional denunciation of RCT ﬁndings: RCTs
are often criticized because they do not support current
practice, denunciation can sometimes appear in pub-
lished forms such as letters to the editor.
Stage 7 – Erosion and discreditation: occurs as more
critical reports appear or when a newer and apparently
more attractive innovation appears.McKinlay's stages map loosely into the marketing product
lifecycle (of introduction, growth, maturity and decline)
[12], but offers an approach that is more relevant to the
adoption of medical devices into complex healthcare set-
tings. McKinlay pointed out that innovations would not
necessarily follow the same trajectory: the stages may
overlap, and not all stages would be relevant to all
innovations [11].
McKinlay's model has been used by other authors to
examine the careers of new medical innovations. In 2005
Wright applied the model to the adoption of hormone
replacement therapy to manage the symptoms associated
with menopause [13]. In 2009 Bo and Herbert studied the
adoption of new physiotherapy treatments [14]. In 2010,
Wall and Brown used the model to describe the history of
earlier incontinence devices that were withdrawn [10].
These studies show that McKinlay's model is relevant to
very different clinical situations. Like McKinlay, these
authors used the model to show that clinical practice is
not in fact anchored in evidence and to argue that innova-
tions should be objectively evaluated prior to their adop-
tion, preferably through RCTs.
We wished to investigate the complete life cycle of TVT
Secur from ﬁrst marketing to discontinuation, and believed
that applying McKinlay's model to this case would shed light
on the possibilities for evidence-driven health care policy.
We chose to use a publicly available source of information,
and opted to review the published literature about TVT
Secur throughout its lifecycle, basing our analysis on
McKinlay's seven stages. Our literature review explored
the role of evidence and the nature of medical knowledge
in the lightly regulated, highly competitive and commer-
cially driven market for midurethral slings.Table 1 Number of papers by year and McKinlay stage.
Year 2007 2008 2009 20
McKinlay stage n=1 n=7 n=10 n=
1 – Promising reports 1 (100%) 3 (43%) 0 0
2 – Professional adoption 0 0 0 0
4 – Standard procedure 0 2 (29%) 6 (60%) 10
5 – RCTs 0 0 0 2
7 – Erosion and discreditation 0 0 0 0
Other reports 0 2 (29%) 4 (40%) 3Method
We carried out a literature review of all papers cited in
PubMed between 2006 and November 2014. Our review
included abstracts of reports that involved “TVT Secur”
(veriﬁed using alternative search terms “TVT Secure” and
“TVT-S” and “mini sling”). All papers were included if they
described new data of any kind, from basic science or case
reports to RCTs. If two papers by the same authors described
the same study, but reported one year outcome in the ﬁrst
paper and two year outcome in the second, both were
included. Clear duplicates were removed, for example a
report of the same trial published in different journals in
different languages. Papers that mentioned TVT Secur only
in their lists of references were excluded.
Data were extracted for each study including year and
journal of publication, author names and countries, study
design, interventions and brief results. For analysis, each
paper was classiﬁed according to the McKinlay seven stages.
An additional “other ”group was used to capture all other
types of published report. Details of the data extraction and
McKinlay stage are provided in an appendix for each of the
papers included in the review.
The unit of analysis was individual papers. Our analysis
described the number and McKinlay stage of the papers
published over time, and within each year the proportion of
papers from each of the relevant McKinlay's stages. Detailed
qualitative analysis was undertaken for each McKinlay's
stage, with consideration of the presence or absence of
papers associated with each individual stage, discussed in
the context of TVT Secur, and the circumstances that may
have been associated with that stage.Results
Our review identiﬁed 83 unique published papers reports
related to TVT Secur (Appendix A). The papers were written
by 58 ﬁrst authors in 23 countries. The reports were
distributed across the years 2007–2014 with most being
published since 2010 (Table 1). Additional tabulation of the
papers classiﬁed by McKinlay stage is presented in Table 2.
Twenty-one papers did not ﬁt a McKinlay stage classiﬁcation:
eleven technical reports [15–25], ﬁve cadaver or animal
studies [26–30] and ﬁve reviews or commentaries [31–35].
Analysis for each McKinlay stage follows (associated
papers from the literature review are cited beside each
stage heading).10 2011 2012 2013 2014 (ﬁrst 10 months)
15 n=14 n=14 n=8 n=14
0 0 0 0
1 (7%) 0 0 0
(67%) 4 (29%) 7 (50%) 2 (25%) 3 (21%)
(13%) 5 (36%) 5 (36%) 3 (38%) 4 (29%)
0 0 1 (12%) 3 (21%)
(20%) 4 (29%) 2 (14%) 2 (25%) 4 (29%)
171Surgical device life cycle analysisStage 1 – Promising reports, n=4 [36–39]
McKinlay described the ﬁrst promising reports of a new
innovation as generally being of poor methodological qual-
ity, and this was the case for the initial reports of TVT Secur.
The studies were small, describing the device as simple to
use and safe, despite the short postoperative follow-up.
Although TVT Secur was the ﬁrst device of its type,
requiring only a single incision and using a much shorter
mesh tape and entirely new absorbable ﬁxation tips, few
preliminary reports were published. A large consideration
for devices is obtaining a license to sell the device in
individual jurisdictions, for example UK, Canada, or USA.
The evidence provided in the licensing process is not
published, and therefore this process is not identiﬁed in
the medical literature. TVT Secur, like many devices in this
area of practice, was licensed in Europe, the US and Canada
on the basis of a predicate licensed moderate risk device, so
that no additional evidence of safety or efﬁcacy was
required [1–4]. Ethicon claimed the device was substantially
equivalent to the company's TVT and TVT-O devices already
on the market, and released the TVT Secur accompanied by
data on the outcome and follow-up of the older devices.
Therefore when TVT Secur was initially marketed, likely it
was not perceived as being sufﬁciently novel to merit
promising reports. Despite the apparent similarities to
TVT, Ethicon needed to convince surgeons that the device
was different enough to change their practice, but this type
of marketing occurred at clinical meetings, through contact
with Ethicon salespeople, and through professional net-
works rather than through scientiﬁc publication.
Stage 2 – Professional and organizational adoption,
n=1 [40]
The competitive nature of the urogynaecology device
market and lack of data about which procedures and
devices are used to surgically treat incontinence means
that we are unable to say how widely TVT Secur was
adopted, or even the rate of its use. One report described
a large industry-funded prospective registry set up to
examine the clinical effectiveness of TVT Secur compared
to TVT and TVT-O [40]. Choice of device depended on
surgeon preference. Data were contributed from February
2007 to June 2009 with follow-up of 1334 women, 49% of
who had a TVT Secur device. It is not clear from the paper
whether all participating surgeons contributed TVT Secur
patients, so it is not obvious whether TVT Secur was widely
adopted even by this apparently committed group.
Stage 3 – Public acceptance and third-party
endorsement, no papers identiﬁed
Third-party endorsement of a new device such as TVT Secur
may often be implicit and determined to a greater degree
by clinicians than payers, so we would not expect to ﬁnd
published reports documenting when and why health care
systems or insurers approved funding for TVT Secur. Because
the newer device (TVT Secur) was licensed as equivalent to
other devices with the same indication, and was similar in
cost, it likely did not trigger cost-beneﬁt analysis orsystematic review by third-party payers. Assuming that
the device is approved for use in the institution where the
surgery is performed, for example through the institution's
health technology assessment process [41] or implicitly
through inclusion in purchasing contracts, it would be the
responsibility of the surgeon to specify which particular
device they would use. Therefore few barriers are present
to adopt a new moderate risk device once it is cleared for
marketing, and the adoption process is likely a matter of
local negotiations, rather than programmatic endorsement.
There has been an increase in public demand for, and
acceptance of, surgical treatment for stress urinary con-
tinence [42] in the wake of the development of the TVT, but
our research [43] and experience suggest that for the most
part women are not given, or in a position to make, a choice
regarding the particular device used for their surgery.Stage 4 – Standard procedure and observational
reports, n=34 [44–77]
Almost half of the research reports identiﬁed in our review
fell into this category, the ﬁrst appearing in 2008. The
studies used a variety of cohort designs that fall short of
formal evaluation to report clinical practice. These studies
were subject to biases inherent in cohort studies and many
included small numbers of patients. Despite these limita-
tions, sweeping generalizations were made about the safety
and effectiveness of TVT Secur (Appendix A). Over time, the
outcomes were seen to be less favorable, reporting more
adverse events and lower effectiveness.Stage 5 – RCTs, n=19 [78–96]
Nineteen papers described results from 15 RCTs (Appendix A).
These more rigorous studies started to appear in 2010,
although the RCTs were small (the largest study recruited
285 subjects [85]). The ﬁrst trials compared the different
approaches used for TVT Secur (“U” where the tape place-
ment is similar to the retropubic TVT tape, versus “H” where
the tape placement is similar to the obturator procedure
[78,79]), with later trials mainly comparing TVT Secur to
Ethicon TVT-O and/or Ethicon TVT. In these RCTs, the
comparisons were bound to produce a favorable outcome
for Ethicon, even when TVT Secur was found to be less
effective than the older types of tape device. Only two RCTs
(3 papers) compared outcomes following TVT Secur to
devices from another manufacturer, ﬁnding outcomes unfa-
vorable to TVT Secur [83,89,95]. It is not possible to
comment on the role of Ethicon in sponsoring RCTs, because
the published reports seldom mention funding sources. Only
four of the RCTs identiﬁed in this review were registered in
ClinicalTrials.gov: of those, Gynecare was mentioned as a
collaborator for only one [91,96].
As anticipated by McKinlay's model, the RCTs produced
outcomes that were less favorable than the cohort studies.
Reports of RCTs continued to appear after notiﬁcation of the
discontinuation of TVT Secur, as a result of the delays in
completing the research, continuing follow-up, and passing
through the peer review process.
Table 2 Number (%) of papers reported for each
McKinlay stage.
McKinlay stage Number of
reports (n=83)
1. Promising reports 4 (5%)
2. Professional adoption 1 (1%)
3. Third-party endorsement 0
4. Standard procedure 34 (41%)
Prospective cohort study 17
Retrospective cohort study 10
Comparative cohort study 7
5. RCTs 19 (23%)a
TVT Secur versus TOT 8
TVT Secur versus TVT 4
TVT Secur “U” versus “H”b 2
TVT Secur versus other device(s) 4
Anesthesia (local versus general) 1
6. Denunciation of RCTs 0
7. Erosion and discreditation 4 (5%)
Other reports 21 (25%)
Technical reports e.g. description of
managing an adverse event
11
Reviews or commentaries 5
Cadaver or animal studies 5
aTrials could include more than two groups.
b“U” technique is akin to retropubic tape placement,
“H” akin to obturator placement.
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no reports identiﬁed
McKinlay described vigorous criticism of RCTs, particularly if
those RCTs threatened established practice. Our review
(which included letters to the editor) found no criticism of
the TVT Secur RCTs, likely because TVT Secur did not
become the stress urinary incontinence surgery device of
choice among surgeons, and many alternative devices
continue to be available. It is also possible that denuncia-
tion of RCTs may yet follow.Stage 7 – Erosion and discreditation, n=4 [97–100]
Our review found four papers that provided explicit evi-
dence of erosion and discreditation, all published since
2013. Two reports were rigorous systematic reviews that
investigated outcomes following single-incision mini-slings:
one a systematic review with meta analysis [97] and one a
Cochrane review [98]. Two additional reviews also report on
outcomes of TVT Secur versus other slings [99,100]. These
reviews came to very similar conclusions: that TVT Secur
was not as effective as the more traditional tape devices
and leads to more adverse effects (such as tape erosions and
reoperations). The reviews found that there was too little
evidence about the outcomes of other single-incision mini-
slings to comment conﬁdently on the outcomes of those
devices: this conclusion is similar to that in earlier reviews
about TVT Secur in 2011 [32,33].Discussion
In his paper, McKinlay identiﬁed major elements in the life
of a medical innovation, which he abstracted into stages for
analytical purposes [11]. McKinlay's model is, essentially, an
ideal-type (or, better, an un-ideal-type), the usefulness of
which does not depend on whether the model encompasses
all the constituent elements in the life of any particular
innovation or whether a particular innovation strictly con-
forms to the stages. McKinlay made clear in this paper that
for any particular innovation there may be variations in the
order of events and whether and how each stage occurs.
We used McKinlay's stages as an heuristic tool for illuminat-
ing a particular case, TVT-Secur. McKinlay's essential point
was that innovations are often adopted prior to the avail-
ability of high-quality clinical evidence (RCTs) of their
effectiveness and efﬁciency, and when this evidence
becomes available, it often shows the innovation to be less
effective or safe than assumed. Our aim was to compare the
events in the life of TVT-Secur against this un-ideal-type. In
this paper, we focus solely on the published literature,
because it is the type of evidence that would have been
available to physicians and policy makers and represents the
evidence that contributed to local and national clinical
guidelines. We wished to examine if published evidence on
the TVT-Secur followed the same course of development
McKinlay isolated in his article. It is remarkable that the
development of published research evidence on TVT-Secur
does indeed display some of the same tendencies McKinlay
identiﬁed 35 years ago, given how far the evidence-based
medicine movement has advanced in the interim. A more
fulsome examination of the history of TVT-Secur is beyond
the scope of this paper, but would use McKinlay's stages to
examine for instance the role of the media in promoting
these or similar devices, the role of formal, but unpub-
lished, means of information sharing (through talks, con-
ference presentations, or workshops) and informal
information-sharing (through peer discussion, use of advo-
cates, etc.) [101]. The particularities of TVT-Secur also
illuminate ways McKinlay's model may fall short as a
description of reality and as a set of policy recommenda-
tions, given the nature of the market for moderate-risk
medical devices.
The complete life cycle of TVT Secur was illustrated by our
review of literature identiﬁed from PubMed. As predicted by
McKinlay's seven stages model [11], the ﬁrst papers were
small case series describing experience with this new device
(stage 1), followed by larger cohort studies with various retro-
spective, prospective and comparative designs and durations of
follow-up (stage 4). Finally randomised studies appeared
comparing outcome between TVT Secur and other types of
sling procedure (stage 5). Stage 7 was represented by reviews
that not only addressed outcomes of TVT Secur, but linked
lower effectiveness and potential harm from the procedure to
the removal of TVT Secur from the market, evidence of
discreditation of the device. McKinlay's 1981 model provided a
valuable structure to explore the short life cycle of this device;
our analysis also shows how the current market and regulatory
system altered TVT Secur's career. The analysis of TVT Secur
draws attention to the potentially powerful role of device
manufacturers as they manage their product portfolio, and to
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for evidence-driven policy and clinical practice. In particular,
rigorous objective evaluation of innovations (preferably through
clinical trials) prior to their introduction, as recommended by
McKinlay and advocated by critics of the commercialization of
medical devices [2–4,9,10], seems increasingly unlikely.
The failure of current regulatory systems for medical
devices, particularly for derivations of moderate risk
devices from predicate devices, has become apparent
[9,102,103]. TVT Secur is only one example of a new device
regulators have cleared as equivalent to a prior licensed
device and Ethicon Gynecare was compliant with all the
requirements of the regulatory bodies worldwide before
marketing their device. Before receiving clearance for
marketing, Ethicon was required to provide evidence of
pull-out strength for the novel, “self-ﬁxating” TVT Secur
tips, but changes from the original TVT device (including the
tips and signiﬁcantly shorter mesh tape) seem to have
signiﬁcantly reduced the procedure's effectiveness. Changes
that did not register as “new” with regulators turned out to
be signiﬁcant, as has been the case with other much-
publicized devices approved on the basis of substantial
equivalence [3,102,104]. In 2011, the Institute of Medicine
(IOM) recommended the FDA eliminate the current 510
(k) process and recognized the inevitable inadequacy of
premarket surveillance [105]. As well, requirement for
premarket surveillance of the vast number of devices
produced each year, especially derivative and moderate
risk devices, would be particularly difﬁcult to regulate.
Changes to political-economic institutions that might create
a more patient-focused balance of innovation and risk are
remote given resistance to regulatory change and the
extent to which corporate interests have redeﬁned and
lowered regulatory standards internationally [106].
Attempts to harmonize international device regulations
have been slow to move forward, although international
standards are being increasingly recognized [1].
Systematic post-marketing evaluation has therefore
become a crucial mechanism to protect patients from harm
[1,107], as recognized in the IOM report [103,105]. This will
require resources, but postmarket evaluation is likely to be
a more efﬁcient and thorough response to the complexities
of innovation in the arena of medical devices, especially
those deemed modiﬁcations of moderate risk. Even if high-
quality evidence from clinical trials was available prior to
marketing, such trials would be unable to provide long-term
outcome evidence of safety and effectiveness that would be
of relevance to clinicians and patients in selecting the best
device [103,108]. Investment in postmarket evaluation will
require commitment from national or local policy makers to
dedicate scarce health care resources to this effort. There
is always risk associated with elective surgery. Health policy
makers must consider the level and degree of risk that is
acceptable without introducing better monitoring and eva-
luation of new device derivations.
Finally, two features of this case stand out because they
were not anticipated in McKinlay's still classic article and
they warrant further study and analysis. One is that litiga-
tion arguably now plays a central role in representing the
welfare of patients and bringing about device discreditation
[109–111]. An internet search using “TVT Secur” and “class
action” identiﬁes many legal groups who aim to bring classaction suits representing women who feel they have been
harmed by the device. The US MAUDE Medical Device
Reports database [112] provides further insight: between
January 2006 and November 2014, the database includes
1655 entries for TVT Secur mainly related to injury. The vast
majority of reports (1546 (93%)) were made in the months of
June to December 2013, following the removal of TVT Secur
from the device market. Many of the MAUDE entries were
instigated by attorneys' reports. These reports could be
considered as evidence of discreditation of the device, or
else a move to support class action lawsuits. We note that
litigation may serve as a quasi-regulator of medical markets
and clinical practice. Second is the interdependence of the
nature of the market and the nature of knowledge. The type
and quality of evidence produced about TVT Secur was
certainly shaped, perhaps determined, by the question of
whether TVT Secur would be proﬁtable. This is especially
apparent in the published RCTs identiﬁed in our study,
where comparisons often included devices solely from the
same manufacturer. In the case of TVT Secur, poor quality
evidence was a characteristic of the early stages of the
device's lifecycle, as McKinlay described, but also its end.
The device came and went without being subjected to the
kinds of assessment now regarded as rigorous and scientiﬁc.
Notwithstanding Ethicon's explanation for the withdrawal of
TVT Secur, the emergence of just enough evidence to call
into question the device's effectiveness, and therefore
market viability, must have been important to the com-
pany's decision, reinforced recently by evidence from
systematic reviews that post-dated TVT Secur's discontinua-
tion [97–100].
In the absence of clear strategies to ensure that deriva-
tive moderate risk devices are thoroughly evaluated before
marketing, there are important issues to be considered by
policy makers and clinicians. Policy makers should under-
stand the level of (or absence of) evidence that supports a
new device that is adopted for use in their institution. They
must realize that adopting a device without evidence may
place their institution and patients at greater risk than using
a device that is supported by evidence. For clinicians who
decide to use a device unsupported by evidence, there is an
ethical need for careful, complete and documented
informed patient consent, describing the lack of evidence
of safety or effectiveness of the new device [113]. Better
tracking systems are needed to know which devices are used
when and correlate them with outcomes [8,107].Conclusion
McKinlay's seven stages [11] provided a useful model to
explore the lifecycle of TVT Secur. Our analysis pointed to
the limitations of the current situation of seeking evidence
only after adoption and funding of new devices, truncation
of scientiﬁc evaluation, lack of rigorous clinical trial evi-
dence, knowledge generation determined by market viabi-
lity, and inadequate evidence at both the start and end of
the device lifecycle. As well, our analysis highlighted the
role of surgeons as the ethical gatekeepers when other
authorities (professional organizations and institutions) do
not provide high standards for adopting new devices.
S. Ross et al.174Our exploration raised many larger issues outside the
restricted topic of TVT Secur that need addressing locally,
nationally and internationally about the adoption and post-
marketing evaluation of moderate risk devices derived from
established devices. It will be essential to establish who
should be responsible for these evaluations, who will be the
best patient advocate and who will pay for this additional
extensive work.
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Table A1 Brief summary details of TVT Secur publications identiﬁed from the PubMed search, 2006 to November 2014.
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
McKinlay stage 1: promising reports
2007 Martan 36 Czechoslo-
vakia
Prospective
cohort
TVT Secur 15 TVT Secur
(10 H, 5 U)
follow-up 1–3
months
NA 93% at 1–3
months
2 tape folded, 1 pain in
vagina, 1 3 mm vaginal
erosion
Both options are
recommended – H might
be better for larger
mobility of urethra, U
better for less mobility
2008 Debodinance 37 France Prospective
cohort
TVT Secur 110 TVT Secur
(94 H, 16 U)
follow-up to
2 months
NA 70% Bladder wound, vaginal
wound, 4 bleeding GT
100 ml. At 2 months de
novo urgency 20%, dysuria
13%, 1 tape exposure,
1 urinary infection,
7 lateral cords
Indications of this new
device to be deﬁned
2008 Gorlero 38 Italy Prospective
cohort
TVT Secur 15 TVT Secur NA 87% No intraoperative
complications, technical
difﬁculties – bleeding,
dislocation/removal of
mesh, need to repeat
procedure
Simple, safe, min invasive,
with short learning curve
2008 Sola 39 Chile Retrospective
cohort
TVT Secur 16 TVT Secur
(6 V, 10 U) ,
follow-up 1–4
months
NA 100% No complication TVT Secur is feasible, safe
and effective for SUI, long-
term follow-up is needed
McKinlay stage 2: professional adoption
2011 Tincello 40 UK Prospective
registry
TVT Secur,
TVT, TVT-O
1398, Postop
data at 1 year –
438 TVT, 237
TVT-O, 659 TVT
Secur
"response"
79% TVT-O,
85% TVT,
85% TVT Secur
96% TVT-O,
87% TVT, 84%
TVT Secur
(cough test)
NA High effectiveness of all
3 tapes
McKinlay stage 4: standard procedures
2008 Jimenez 44 Spain Comparative
cohort
TVT Secur,
MiniArc
51 TVT Secur, 41
MiniArc (all H)
follow-up 5–17
months
NA 80% TVT Secur,
90% MiniArc
Fewer complications than
TVT, TVT-O, further
studies needed
2008 Neuman 45 Israel Prospective
cohort
TVT Secur
(H)
100 Consecutive
TVT Secur H (cf
1st and 2nd 50)
NA 89%, 94% (1st
cf 2nd 50)
Early group complications
– 4 vaginal wall
penetrations with
inserters, 2 tape tension
TVT Secur associated with
early safety and efﬁcacy
problems. Need for
meticulous and proper
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Table A1 (continued )
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
requiring surgery,
1 hematoma, 5 removal
when inserters removed,
6 tape extrusion.
Technique modiﬁed for
second group – 4 tape
extrusion
dissection before
placement of tape
2009 Debodinance 46 France Prospective
cohort
TVT Secur 154 TVT Secur,
follow-up 12
months
NA 70% Peroperative
complications:
5 hemorrhage, 12 bladder
injury, 1 vaginal wound.
Postop, 2 exposed tapes,
1 granuloma, 1 UTI,
7 lateral vaginal bands
Results considered inferior
to TVT or TVT-O
2009 Martan 47 Czechoslo-
vakia
Prospective
cohort
TVT Secur 85 TVT Secur NA 62% (cough
test)
Objective cure was low,
perhaps because of
insufﬁcient restriction of
urethral mobility
2009 Meschia 48 Italy Prospective
cohort
TVT Secur 91/95 TVT
Secur, follow-up
at 1 year
78% 81% Voiding difﬁculty,
recurrent UTI, de-novo
urgency, dyspareunia
TVT Secur has 80% success
rate
2009 Oliveira 49 Portugal Prospective
cohort
TVT Secur 107 TVT Secur,
mean follow-up
of 15 months
69% 71% Urgency de novo in 6%,
1 vaginal erosion
Simple and safe, needs
long-term follow-up
2009 Sola 50 Chile Prospective
cohort
TVT Secur 110 TVT Secur,
follow-up 2–19
months
96% NA 2 bladder perforations,
2 obstruction
Has potential avantages vs
older techniques, long-
term follow-up needed
2009 Tartaglia 51 Italy Retrospective
cohort
TVT Secur
(H)
32 TVT Secur H,
follow-up 12–18
months
100% NA No surgical complicatons,
1 erosion
Safe and easy, may have
fewer complications
2010 Alvarez 52 Spain Retrospective
cohort
TVT Secur,
MiniArc
50 TVT Secur,
105 MiniArc,
follow-up over
26 days
NA NA Complication rate 22% TVT
Secur, 17% MiniArc.
1 bladder perforation.
(early comp all in MiniArc.)
5% vaginal erosion, 4%
urethral obstruction, 1%
recurrent infections
surgery with mini-slings “is
not without complications
(20%)”
2010 Cornu 53 France Prospective
cohort
TVT Secur 45 consec TVT
Secur +/ POP,
follow-up at
NA 40% Cure
(composite) at
last follow-up
5 de novo OAB, 3 UTI. 12
Patients needed additional
SUI surgery during follow-
up
…“despite its good short-
term efﬁcacy, TVT Secur is
associated with a high
recurrence rate of SUI”
S.
Ross
et
al.
176
11–40 months –
see also [67]
2010 Gagnon 54 Canada Prospective
cohort
TVT Secur 48 TVT Secur
ﬁrst 23 H, last
26 U, LA,
outcome at 6mo
Improved
sympts 69% H
vs 100% U
NA 6 partial tape exposures
all with H
Short term efﬁcacy better
for U, long term outcome
to be determined
2010 Jeong 55 Korea Comparative
cohort
TVT Secur,
Monarc
64 (31 TVT
Secur, 33
Monarc), follow-
up over 1 year
NA 71% TVT Secur,
85% Monarc
No signiﬁcant
complications
TVT Secur and Monarc may
be comparable for cure
and satisfaction
2010 Joo 56 Korea Comparative
cohort
TVT Secur,
CureMesh
60 (38 TVT
Secur, 22
CureMesh)
follow-up to
1 year
NA 68% TVT Secur,
77% CureMesh
No intraoperative
complications
Both are safe and simple.
Long-term studies needed
2010 Khandwala 57 USA Retrospective
cohort
TVT Secur 141 TVT Secur,
follow-up at
6 months
83% NA No intraoperative
complications
TVT Secur is safe and
effective for SUI
2010 Krofta 58 Czechoslo-
vakia
Prospective
cohort
TVT Secur 86, 84
Followed-up at
1 year
60% 52% Vaginal defect healing in
5, urethral erosion in 1
“Objective and subjective
cure rates following TVT
Secur are inferior to other
tape procedures”
2010 Liapis 59 Greece Prospective
cohort
TVT Secur
(H,U)
TVT Secur
(43 H, 39 U)
follow-up at
1 year
61% H, 69% U 63% H, 72% U No signiﬁcant adverse
events
Comment – efﬁcacy of TVT
Secur was lower than
other (published) TVT cure
rates
2010 Lim 60 Australia Prospective
cohort
TVT Secur
(U)
TVT Secur 42
(recruitment
stopped early),
follow-up to
6 months
51% 58% UTI, voiding difﬁculty,
groin discomfort,
hematoma, vaginal pain,
tape erosion, intra-op
dislodgement of tape, de
novo urge 10%
Ceased early because of
high of early failures.
Claims of advantages “may
be at the expense of a
signiﬁcant learning curve
and a higher early failure
rate”. TVT Secur not
recommended on basis of
this limited study
2010 Tommaselli 61 Italy Comparative
cohort
TVT-O, TVT
Secur
84 (38 TVT-O, 37
TVT Secur)
follow-up to
1 y ear
82% TVT-O, 84%
TVT Secur
NA Complication rate TVT
Secur 8%, TVT-O 16%
Effective, safe and low
incidence of complications
2011 Chen 62 China Retrospective
cohort
TVT Secur 30, Follow-up to
12 months
NA 60% at 12
months
OAB in 23% at 12 months “TVT Secur has a high rate
of recurrence of SUI”
2011 Neuman 63 Israel Comparative
cohort
TVT-O, TVT
Secur
162 (outcomes
available for 60
TVT-O and 77
91% TVT Secur,
87% TVT-O
NA Transient thigh pain in
TVT-O (32% vs 1% in TVT
Secur). Dyspareunia
Thigh pain more frequent
in TVT-O (32% vs 1%), 177
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Table A1 (continued )
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
TVT Secur)
follow-up over
36 months
occurred more frequently
in TVT Secur group (8% vs
0%). Other complications
similar
dyspareunia more common
in TVT Secur (8% vs 0)
2011 Pushkar 64 Russia Comparative
cohort
TVT Secur,
TVT-O
32 TVT Secur, 40
TVT-O, follow-
up to 6 months
Positive result:
62% TVT Secur,
95% TVT-O
NA NA Failed for 5 TVT Secur.
TVT-O is more effective
than TVT Secur
2011 Shin 65 Korea Retrospective
cohort
TVT Secur 51, Follow-up to
2 years, data
available for 46
76% NA No complications “TVT Secur is an efﬁcient
and safe procedure”
2012 Bernasconi 66 Italy Prospective
cohort
TVT Secur
(H, U)
110 H, 26 U,
follow-up to
2 years
93% 6mo, 92%
12 months, 92%
24 months
(cough test)
88% 6 months,
89% 12 months,
89% 24 months
Vaginal erosions in 2% at 24
months
Safe, effective, but “has
an appreciable learning
curve”
2012 Cornu 67 France Prospective
cohort
TVT Secur Update on
(Cornu 2010
[53]) plus
9 patents (i.e.
54), follow-up
at median 59
months
NA 31% Cure
(composite)
Reoperation in 29%
because of failure
TVT Secur results worsen
with time…No severe as
during follow-up
2012 Han 68 Korea Prospective
cohort
TVT Secur
(H,U)
96 (42 H, 54 U),
follow-up for GE
3 years
73% 3-year NA 3 perforation of anterior
vaginal wall, 13% de novo
urgency, 19% UUI, vaginal
erosion in 1 H and 1 U,
6 had further procedures
for new/persistent SUI
Success (but not cure)
maintained
2012 Hwang 69 S Korea Comparative
cohort
TVT Secur,
TOT
89 TVT Secur, 86
TOT, follow-up
GE 1 year
71% vs 91%
(survey or
stress test)
NA No signiﬁcant differences
in complications. 2 TVT
Secur patients required
reoperation
TVT-O superior to TVT
Secur
2012 Khandwala 70 USA Prospective
cohort
TVT Secur
(H)
50 TVT Secur H,
follow-up at
24mo
NA 80% Success
(composite),
9% reoperation
No intraop or postop
complications. 2 vaginal
mesh exposure
In-ofﬁce procedures are
safe, feasible, successful
with minimal
complications
2012 Richard 71 Canada Retrospective
cohort
TVT Secur
(U)
33 TVT Secur,
1 year follow-up
78% 63% 1 BOO, no complaint of
voiding symptoms
2012 Tommaselli 72 Italy Retrospective
cohort
TVT Secur
(H)
68 TVT Secur,
2yr follow-up
NA 81% Intraop – 1 vag wall tear,
1 severe bleed; post-op –
TVT Secur is safe and
effective
S.
Ross
et
al.
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5 urgency, 1 retention,
1 tape exposure
2013 Tang 73 China Prospective
cohort
TVT Secur 33 TVT Secur,
follow-up to 12
months
NA 78% 1 erosion found at 12
months
“Objective cure rate not
high” TVT Secur said to be
“minimally invasive, safe
and effective”
2013 Abduljabbar 74 Saudi
Arabia
Retrospective
cohort
TVT Secur,
TVT
230 (81 TVT
Secur, 149 TVT)
follow-up at
6 months
NA NA Note – cannot
differentiate between TVT
Secur/TVT. 4% bladder
perforation, 23% bladder
retention at 24 h, 3 cases
of erosion
TVT Secur and classical
TVT were found to be
effective, easy and safe
procedures
2014 Angleitner-
Flotzinger
75 Austria Retrospective
cohort
TVT Secur 158 TVT Secur –
96 followed-up
at 5–50 months
46% 30% (cough
test)
8% Reoperation, no tape
erosion/exposure, 21% de
novo urgency, 4%
dyspareunia
TVT Secur appears to have
low adverse events but
inferior results compared
to traditional midurethral
slings
2014 Bourdy 76 France Retrospective
cohort
TVT Secur,
TVT-O
371 (29 TVT
Secur, 342 TVT-
O) follow up
median 4 years
NA NA Exposures: TVT Secur 14%,
TVT-O 4%
TVT Secur seems less
efﬁcient than traditional
slings and gives rise to
more exposure
2014 Luo 77 China Prospective
cohort
TVT, TVT-O,
TVT Secur
453 Consecutive
patients (105
TVT, 243 TVT-O,
90 TVT Secur, 15
TVS)
97% TVT, 100%
TVT-O, 99%
TVT Secur,
100% TVS
NA Only minor complications
were experienced by the
patients
Each sling procedure was
found to be safe and
effective
McKinlay stage 5: RCTs
2010 Kim 78 Korea RCT TVT Secur
(U, H)
115 (53 U, 62
H), follow-up at
1yr
NA 88% U, 87% H 3 Vaginal wall perforation
(H), postop retention for 3
(2 U, 1 H)
Comparable effectiveness
for U and H
2010 Lee 79 Korea RCT TVT Secur
(U, H)
285 TVT Secur
(144 U, 143 H)
follow-up at
1 year
77% U, 76% H 88% U, 80% H 3 intraop vaginal wall
perforation, 1 increased
bleeding, 3 temporary
postop retention (group
not explicit)
H and U TVT Secur
provided comparable cure
rates for women with SUI
2011 Andrada 80 Sweden RCT TVT, TVT
Secur
125 rand, 123
(62 TVT, 61 TVT
Secur) follow-up
at 2 months –
see [90]
92% TVT, 72%
TVT Secur
NA Tape erosion into urethra,
tape placed inside bladder,
immed postop bleed from
corona mortis
TVT Secur lower subj cure,
3 serious AEs therefore
discourage further use.
See also 3
2011 Araco 81 Italy RCT Local vs
general
anesthesia
80 TVT Secur
(40 local, 40
general)
NA NA Postoperative
complications 8% in each
group
Local anesthesia reduces
pain and shortens hospital
stay
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Table A1 (continued )
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
for TVT
Secur(H)
2011 Hinoul 82 Belgium RCT TVT Secur,
TVT-O
96 TVT Secur, 98
TVT-O, follow-
up 1 year
76% TVT Secur,
92% TVT-O
84% TVT Secur,
98% TVT-O
TVT Secur: 7 tape
exposures, 14 reoperations
for SUI. TVT-O: 1 tape
exposure
TVT Secur gave less postop
pain, lower objective cure
rate, more re-intervention
2011 Oliveira 83 Portugal RCT TVT-O, TVT
Secur,
MiniArc
90 (30 TVT-O, 30
TVT Secur, 30
MiniArc),
follow-up to 12
months
NA 83% TVT-O, 67%
TVT Secur, 87%
MiniArc
No intraoperative
complications. Postop
2 TVT-O required surgical
release of tape for
retention. Other
complications – transient
urinary retention, de novo
urgency, thigh pain (2 TVT-
O, 1 MiniArc)
"TVT Secur may yield an
inferior outcome"
2011 Wang 84 China RCT TVT, TVT-O,
TVT Secur
102 (32 TVT, 36
TVT-O, 34 TVT
Secur), follow-
up to 1 year
94% TVT, 92%
TVT-O,
68% TVT Secur
NA TVT – 1 bladder
perforation, 3 urine
retention, 5 urgency; TVT-
O – 1 urine retention,
5 pain in thigh, 6 urgency;
TVT Secur – 1 bladder
perforation, 12 urgency
TVT Secur "had rare
complications but
unsatisfactory efﬁcacy,
and we suggest it is not ﬁt
for severe cases"?
2012 Barber 85 USA RCT TVT Secur
(U), TVT
126 TVT, 136
TVT Secur,
follow-up to
1 year
57 % TVT Secur,
61% TVT
NA TVT Secur – 1 bladder
perforation, no mesth
exposure, 2 sling release;
TVT – 6 bladder
perforations, 1 mesh
exposure at 6 weeks,
3 sling release
TVT Secur results in
"similar subjective cure
rates to TVT 1 year after
surgery, but postoperative
incontinence severity is
greater…."
2012 Hota 86 USA RCT TVT Secur
(H), TVT-O
43 TVT Secur, 44
TVT-O follow-up
to 1 year
TVT Secur cure 48% TVT Secur,
91% TVT-O
(cough stress
test)
TVT Secur – 19%mesh
exposure requiring
surgery. TVT-O – no mesh
exposure
More pos cough in TVT
Secur but QOL/satisfaction
similar (study terminated
early)
2012 Masata 87 Czechoslo-
vakia
RCT TVT-O, TVT
Secur (H, U)
(3 group)
68 TVT-O, 64
TVT-SH, 64 TVT-
SU follow-up
3 months – see
[87]
91% TVT-O,
82% TVT-SH,
78% TVT-SU
95% TVT-O,
82% TVT-SH,
78% TVT-SU
Tape exposure, 8% TVT-SH,
6% TVT-SU, 1% TVT-O.
Reoperation, 1% TVT-SH,
1% TVT-SU, 0% TVT-O
Lower subj, obj cure in
TVT Secur groups at
3 months
2012 Masata 88 Czechoslo-
vakia
RCT TVT-O, TVT
Secur (H, U)
(3 group)
68 TVT-O, 64
TVT-SH, 64 TVT-
SU follow-up
85% TVT-O,
69% TVT-SH,
62% TVT-SU
93% TVT-O,
69% TVT-SH,
69% TVT-SU
TVT-O – 2% erosions, no
reoperations: TVT-SH – 8%
erosions, 19%
Lower subj, obj cure in
TVT Secur groups at 1 year
S.
Ross
et
al.
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median 2 years
(GE 0.1 year) –
see [87]
reoperations: TVT-SU –6%
erosions, 14% reoperations
2012 Palomba 89 Italy RCT TVT Secur,
MiniArc,
Ajust
40 TVT Secur, 40
MiniArc, 40
Ajust, follow-up
at 30 days – see
[95]
NA NA TVT Secur group –
2 intraoperative
hemorrhage, 4 postop pain
greater than 7, 1 obturator
hemorrhage (Ajust 1 pain
greater than 7, MiniArc no
complications). At 30 day
follow-up, no erosions.
Other postop
complications included
UTI, de novo urge, self-
catheterisation of more
than 7 days
MiniArc safer than TVT
Secur
2013 Andrada 90 Sweden RCT TVT vs TVT
Secur
133 rand, 121
follow-up at 1yr
(61 TVT, 60 TVT
S) – see [80]
80% TVT Secur,
98% TVT
71% TVT Secur,
94% TVT-O
(cough), 58%
TVT Secur, 76%
TVT-O (pad)
1 Tape erosion into
bladder, one tape placed
into bladder, one injury to
corona mortis
TVT Secur less effective,
3 serious AEs therefore
discourage further use.
See also 21.
2013 Bianchi-
Ferraro
91 Brazil RCT TVT Secur,
TVT-O
122 rand, 56
TVT-O, 66 TVT
Secur, follow-up
12 months – see
[96]
92% TVT Secur,
91% TVT-O
84% TVT Secur,
87% TVT-O
TVT Secur: less thigh pain,
complications, vaginal
mucosa perforation,
urinary retention, urinary
infection, de novo urgency
TVT Secur was not inferior
to TVT-O
2013 Tommaselli 92 Italy RCT TVT-O, TVT
Secur
154 rand, 77
TVT-O, 77 TVT
Secur, follow-up
to 36 months
75% TVT Secur,
80% TVT-O
78% TVT Secur,
86% TVT-O
Postoperative
complications 13 TVT
Secur, 14%. Mesh exposure
5% TVT Secur, 3% TVT-O
TVT Secur not inferior to
TVT-O, causes less postop
pain. Cannot rule out
possibility of severe blood
loss
2014 Tang 93 China RCT TVT Secur,
TVT-O
39 TVT Secur,
42 TVT-O,
follow-up to
2 years
NA 74% TVT Secur,
83% TVT-O
(cough)
Groin /thigh pain, 3% TVT
Secur, 19% TVT-O 19%;
tape erosion, 3% TVT
Secur, 7% TVT-O;
dyspareunia, 3% TVT
Secur, 7% TVT-O
The 2 techniques seem to
be equally effective for
SUI treatment, but TVT-O
resulted in a higher rate of
groin/thigh pain
2014 Maslow 94 Canada RCT TVT Secur,
TVT-O
56 TVT Secur,
50 TVT-O,
follow-up to
1 year
63% TVT Secur,
88% TVT-O
63% TVT Secur,
86% TVT-O
Groin pain was more
prevalent in TVT-O but
resolved over time
TVT-O was superior to TVT
Secur in objective cure of
stress urinary incontinence
2014 Palomba 95 Italy RCT TVT Secur,
MiniArc,
Ajust
40 TVT Secur,
40 MiniArc, 40
Ajust, follow-up
53% TVT Secur,
65% MiniArc,
53% Ajust
43% TVT Secur,
55% MiniArc,
48% Ajust
Pelvic pain, 3% TVT Secur;
new/worse urge, 3%
MiniArc, 3% Ajust; erosion,
3% Ajust
The long-term efﬁcacy
does not differ between
the devices studied 181
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Table A1 (continued )
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
at 24 months –
see [89]
2014 Bianchi-
Ferraro
96 Brazil RCT TVT Secur,
TVT-O
122 rand, 56
TVT-O, 66 TVT
Secur, follow-up
2 years – see
[91]
76% TVT Secur,
80% TVT-O
77% TVT Secur,
83% TVT-O
Thigh pain: TVT Secur, less
thigh pain. Tape exposure:
TVT Secur 7%, TVT-O 5%
Efﬁcacy of TVT Secur was
similar to that of TVT-O
after 2 years
McKinlay stage 7: erosion and discreditation
2014 Nambiar 97 UK Systematic
review
Single-
incision
slings
18/31 of the
included trials
included at
least one arm
being TVT Secur
Mini slings
(mainly TVT
Secur) were
less effective
than
transobturator
and retropubic
tapes
Mini slings
(mainly TVT
Secur) were
less effective
than
transobturator
and retropubic
tapes
The adverse event rate
was higher for mini slings
(mainly TVT Secur}
TVT Secur is inferior to
standard midurethral
slings for the treatment of
women with stress
incontinence and has
already been withdrawn
from clinical use
2014 Mostafa 98 UK Systematic
review
Single-
incision
slings
26–12 RCTs
(1606 patients)
compared TVT
Secur to
"standard
midurethral
slings"
NA NA TVT Secur vs other
midurethral slings, mean
difference (95% CI) –
vaginal tape erosion 2.39
(1.19–4.79). Repeat
surgery 4.61 (1.06–20.15),
favouring midurethral
slings
Analyses of TVT Secur
trials were done
separately, ﬁnding that
standard treatment was
favoured over TVT Secur
for patient reported
outcomes. In the analyses
without TVT Secur, there
was no difference between
the outcome of single-
incision mini-slings and
standard midurethral sling
procedures at midterm
follow-up
2013 Castellier 99 France Literature
review
Single-
incision
slings (only
mentioned
TVT Secur
as
comparison
mini-sling)
Review
including 43
papers
(comparative
and prospective
studies)
reporting
ﬁndings for
single incision
slings
NA 40–83% TVT
Secur, 69–92%,
MiniArc, 80–
91% Ajust, 87%
Needleless,
95% Solyx, 85%
Ophira
NA Among single-incision
mini-slings, adjustable
mini-slings provide the
best compromise in terms
of effectiveness and
complications. Comments
on withdrawal of TVT
Secur for commercial
reasons, because it was
S.
Ross
et
al.
182
less effective than other
devices
2014 Lizee 100 France Systematic
review
Single-
incision
slings (only
mentioned
TVT Secur
as
comparison
mini-sling)
NA NA NA NA TVT Secur trials were
speciﬁcally excluded from
the review, which
concluded there was
insufﬁcient data to
support single-incision
mini-slings as standard of
care
Other reports
2012 Palma 30 Brazil Animal Rat model – pull
out force of
different
minislings
2011 Hubka 27 Czechoslo-
vakia
Cadaver
studies
TVT Secur 18 Bodies
(13 embalmed,
5 fresh frozen)
2009 Hubka 28 Czechoslo-
vakia
Cadaver
studies
TVT Secur 19 Bodies
(14 embalmed,
5 fresh frozen)
Signiﬁcant risk of inserting
TVT Secur inserters into
obturator fossa
2013 Stavropoulou 28 Greece Cadaver
studies
10 Female
cadavers
Window of at least 8 mm
between margin of TVT
Secur and aberrant veins
(of corona mortis)
2010 Hubka 29 Czechoslo-
vakia
Cadaver
studies
TVT Secur Comment on contact with
corona mortis
2008 Molden 31 USA Commentary TVT Secur Little data is available
regarding safety and
efﬁcacy, long-term follow-
up needed
2011 Walsh 32 Australia Systematic
review
TVT Secur 10 Studies
included
76% 76% Vag perf 1.2%, mesh exp
2.4%, OAB de novo 10%.
Urinary retn 2%, UTI 4%,
dyspareunia 1%. Rpt
surgery reqd by 5%
Longer term studies are
needed
2011 Oliveira 33 Spain Review Single
incision
slings
16 Papers
included
"Techniques (of single
incision slings) are easy
and seem to require a
short learning curve,
exception being TVT Secur
(TM)"
2012 Zhou 34 China Meta analysis TVT Secur,
TVT-O/TVT
7 RCTs TVT Secur gives less
postop inner thigh and
groin pain, lower objective
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Table A1 (continued )
Year First author Ref Type of study Device
description
Study
description
TVT Secur cure
– subjective
TVT Secur cure
– objective
TVT Secur adverse events Comments/conclusions
cure and higher rates of de
novo urgency and re-
operation
2014 Leanza 34 Italy Systematic
review
Single-
incision
slings
Review of TVT
Secur, Miniarc,
Monarc vs TOT
NA 80–97% TOT,
76–90% TVT
Secur, 56–97%
MiniArc, 81–
95% Monarc
Urethral/vaginal
perforation: Rare TOT,
2-5% TVT Secur, 0-3%
MiniArc, 2% Monarc
A clear statement in favor
of the widespread use of
single incision slings
cannot be made. More
studies must deﬁne the
efﬁcacy of these
techniques
2008 Masata 15 Czechoslo-
vakia
Case report TVT Secur
(H)
TVT Secur H Severe bleeding from
internal obturator muscle,
required surgical
intervention
2009 Hazenwinkel 16 Netherlands Prospective
cohort
TVT Secur
for Ca
patients
(avoid
pelvic
cavity)
2 Ca patients,
TVT Secur
NA Both continent 1 Small tape erosion TVT Secur gives satisfying
results postop, additional
postop care may be
needed
2009 Martan 17 Czechoslo-
vakia
Retrospective
cohort
TVT Secur
(tape
shortening)
8 with
persistent SUI
after TVT Secur
NA 6/8 Patients
cured
Repair is simple, effective,
cheaper than inserting
new tape
2009 Roth 18 USA Case report TVT Secur Dyspareunia for
patient and
husband
because of
retained ﬁnger
pad from
device. Sling
also
malpositioned
Retained ﬁnger pad from
device
Recommendations for
surgeons to avoid such
adverse events
2010 Larsson 19 Sweden Case report TVT Secur 1 Case, injury of
corona mortis
Surgical intervention with
removal of 1 L of clotted
blood from space of
Retzius
2010 Jung 20 Korea Case report TVT Secur Pudendal artery injury
(treated with radiological
embolization)
Angiography with vessel
embolozation should be
considered
2011 Gobrecht 21 Switzerland Case report TVT Secur
S.
Ross
et
al.
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